Diazabicyclononene derivatives and use thereof

Details Diazabicyclononene derivatives and use thereof Diazabicyclononene derivatives and use thereof

2011-03-29

2011-03-29

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S349000

Reexamination Certificate

active

07915259

ABSTRACT:
The invention relates to a novel 3,9-diazabicyclo[3.3.1]nonene derivative of formula (I), enantiomers thereof, and their use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing at least one compound of formula (I):or (I′):and especially their use as inhibitors of renin.

REFERENCES:
patent: 6051712 (2000-04-01), Binggeli et al.
patent: 6150526 (2000-11-01), Binggeli et al.
patent: 2005/0176700 (2005-08-01), Bezencon
patent: 2006/0217371 (2006-09-01), Bezencon
patent: 2006/0223795 (2006-10-01), Bezencon
patent: WO03/093267 (2003-11-01), None
patent: WO2004/096116 (2004-11-01), None
patent: WO2004/096804 (2004-11-01), None
patent: WO2004/105762 (2004-12-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 and 365.
U.S. Appl. No. 11/915,594, filed Sep. 4, 2008, Bezencon, et al.
Waeber B. et al., “The renin-angiotensin system: role in experimental and human hypertension”, Handbook of Hypertension, vol. 8, 1986, pp. 489-519.
Weber M. A., “Clinical Experience With the Angiotensin II Receptor Antagonist Losartan”, Am. J. Hypertens., 1992, 5, pp. 247s-251s.
Rosenberg M. E. et al., “The paradox of the renin-angiotensin system in chronic renal disease”, Kidney International, 1994, vol. 45, pp. 403-410.
Breyer J. A. et al., “Angiotensin converting enzyme inhibition in diabetic nephropathy”, Kidney International, 1994, vol. 45, pp. S156-S160.
Vaughan D. E. et al., “Angiotensin converting enzyme inhibitors and cardiovascular remodelling”, Cardiovasc. Res., 1994, vol. 28, pp. 159-165.
Fouad-Tarazi F. et al., “The Renin-Angiotensin System and Treatment of Heart Failure”, Am. J. Med., 1988, vol. 84 (Suppl. 3A), pp. 83-86.
Pfeffer M A et al, “Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial inraction” N. Engl. J. Med., 1992, pp. 669-677.
Kleinert H. D., “Renin Inhibition”, Cardiovasc. Drugs and Therapy, 1995, vol. 9, pp. 645-655.
Husain A., “The chymase-angiotensin system in humans” J. Hypertens., 1993, vol. I I, pp. 1155-1159.
lsraili Z. H. et al., “Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy” Annals of Internal Medicine, 1992, vol. 117, pp. 234-242.
Azizi M. et al., “Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension” J. Hypertens.,1994,12, 419-427.
Neutel J M et al, “Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat” Am. Heart,1991, 1094-1100.
Rahuel J. etal., “Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin”, Chem. Biol., 2000, vol. 7, pp. 493-504.
Mealy N. E., “Aliskiren Fumarate”, Drugs of the Future, 2001, vol. 26, pp. 1139-1148.
Oefner C. et al., “Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?”, Chem. Biol., 1999, vol. 6, pp. 127-131.
Marki H. P. et al., “Piperidine renin inhibitors: from leads to drug candidates”, IL Farmaco, 2001, vol. 56, pp. 21-27.
Gould, Philip, “Salt selection for basic drugs”, International Journal of Pharmaceutics, 1986, vol. 33, pp. 201-217.
Mark Gibson, Editor, Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood, Co, USA, 2001.
Majewski M. et al., “Synthesis of Tropane Alkaloids via enantioselective deprotonation of tropinone”, J. Org. Chem., 1995, vol. 60, pp. 5825-5830.
Fischli W, etal., “Ro 42-5892 is a potent orally active renin inhibitor in primates”, Hypertension, 1991, vol. 18, pp. 22-31.

Affiliated with

Also associated with

Rating

Diazabicyclononene derivatives and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diazabicyclononene derivatives and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diazabicyclononene derivatives and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2747680